NCT05136443View on ClinicalTrials.gov

Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

September 5, 2023

Study Completion Date

September 5, 2023

Conditions
Corneal Endothelial DystrophyCorneal Edema
Interventions
DRUG

loteprednol etabonate 0.25% ophthalmic suspension

tapering dose

Trial Locations (1)

46260

Price Vision Group, Indianapolis

Sponsors
All Listed Sponsors
collaborator

Kala Pharmaceuticals, Inc.

INDUSTRY

lead

Price Vision Group

INDUSTRY